Advertisement

Topics

Latest PulmoXen NewsRSS

18:33 EST 9th December 2018 | BioPortfolio

Abeona Therapeutics Details Pathway for Advancing Lead Clinical Programs and Unveils New Cystic Fibrosis Program Born from Next Generation AIM™ Vector Platform at 2018 R&D Day

EB-101 pivotal trial for Recessive Dystrophic Epidermolysis Bullosa planned for mid-2019 enrollment Expanding Phase I/II study of ABO-102 for Sanfilippo syndrome type A (MPS IIIA) Novel AIMTM AAV vector with CFTR minigene addresses all mutations of Cystic Fibrosis NEW YORK and CLEVELAND, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage b...

STAT Plus: @VertexPharma is under pressure to hash out a price for its cystic fibrosis drug with U.K. regulators. Will the company blink? https://buff.ly/2RuiTuu 

STAT Plus: @VertexPharma is under pressure to hash out a price for its cystic fibrosis drug with U.K. regulators. Will the company blink? https://buff.ly/2RuiTuu 

STAT Plus: Posturing and bickering have infuriated cystic fibrosis patients and their families for more than two years of protracted talks. https://buff.ly/2EdVAC3 

STAT Plus: Posturing and bickering have infuriated cystic fibrosis patients and their families for more than two years of protracted talks. https://buff.ly/2EdVAC3 

STAT Plus: Will Vertex finally reach a deal with the U.K. over its cystic fibrosis drug?

Posturing and bickering have infuriated cystic fibrosis patients and their families for more than two years of protracted talks.

ChemomAb Appoints Dr. Stephen Squinto as Chairman of the Board

ChemomAb today announced the appointment of Dr. Stephen Squinto as the company’s chairman of the board. In this role, Dr. Squinto will help guide the company as it continues the clinical development of its lead compound towards advanced clinical trials. “Dr. Squinto has led numerous biotech and pharmaceutical firms and his vast...

NuvoAir Redefines Home Monitoring for Cystic Fibrosis Patients

THE FINDINGS from a pilot study into a new way of caring for those with cystic fibrosis (CF) have just been released. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181203005846/en/ NuvoAir Air Next Spirometer and the Aria App (Photo: Business Wire) An

Ninjurin1 Plays a Crucial Role in Pulmonary Fibrosis by Promoting Interaction between Macrophages and Alveolar Epithelial Cells

Link between Celiac Disease, Cystic Fibrosis May Lead to Gluten Intolerance Drugs

Overly thick and sticky mucus contributes to cystic fibrosis and several other diseases, including chronic bronchitis and chronic obstructive pulmonary disease. All these diseases involve the lungs, but thick and sticky mucus can also be a problem elsewhere—the intestine. Curiously, the molecular mechanism that accounts for thick mucus in the lungs also leads to thick […] The post Link bet...

GENFIT: Launch of a U.S. Phase 2 investigator-initiated study with nitazoxanide in patients with NASH-induced fibrosis $GNFT https://globenewswire.com/news-release/2018/12/03/1660476/0/en/GENFIT-Launch-of-a-U-S-Phase-2-investigator-initiated-study-with-ni

GENFIT: Launch of a U.S. Phase 2 investigator-initiated study with nitazoxanide in patients with NASH-induced fibrosis $GNFT https://globenewswire.com/news-release/2018/12/03/1660476/0/en/GENFIT-Launch-of-a-U-S-Phase-2-investigator-initiated-study-with-nitazoxanide-in-patients-with-NASH-induced-fibrosis.html …

Hardman & Co Research: RedX Pharma (REDX): RXC006: First fibrosis development candidate

Hardman & Co Research 30-Nov-2018 / 08:45 GMT/BST Hardman & Co Research: RXC006: first anti-fibrosis development candidate REDX is a clinical-stage biotechnology company focused on drugs targeting oncology and fibrotic diseases. An extensive review, led by the new CEO, has reinforced the vision of a streamlined pipeline in these two disease areas, with the aim of progressing drug ca...

Vertex’s Drug Receives Nod From EU

KALYDECO is a cystic fibrosis drug for patients with certain mutations in the CFTR gene it is now for patients between aged 12 and 24 months. The post Vertex’s Drug Receives Nod From EU appeared first on Investing News Network.

Vertex’s Cystic Fibrosis Drug Receives Nod from EU

KALYDECO is a cystic fibrosis drug for patients with certain mutations in the CFTR gene. It is now for patients aged 12 and 24 months. The post Vertex’s Cystic Fibrosis Drug Receives Nod from EU appeared first on Investing News Network.

Breakthrough Triple Therapies for Cystic Fibrosis

Triple-combination therapy that targets the protein mutation in cystic fibrosis shows potential to improve the lives of 90% of those affected.

Vertex Announces European Commission Approval for KALYDECO® (ivacaftor) to Treat Patients with Cystic Fibrosis Aged 12 to <24 months with Certain Mutations in the CFTR Gene

Ivacaftor is the first and only approved medicine in Europe to treat the underlying cause of cystic fibrosis in these young patients Vertex Pharmaceuticals (Europe) Limited today announced that the European Commission has granted approval of the label extension for KALYDECO® (ivacaftor) to include the treatment of people with cystic fibrosis (CF) aged...

With positive data behind it, a Boston-based #biotech takes a step closer towards its long-stated goal of marketing new therapies capable of treating 90 percent of the genetic mutations that cause cystic fibrosis. https://buff.ly/2ArdX2n 

With positive data behind it, a Boston-based #biotech takes a step closer towards its long-stated goal of marketing new therapies capable of treating 90 percent of the genetic mutations that cause cystic fibrosis. https://buff.ly/2ArdX2n 

Vertex posts positive data from cystic fibrosis triple combo trials https://reut.rs/2RiGtuj 

Vertex posts positive data from cystic fibrosis triple combo trials https://reut.rs/2RiGtuj 

With new clinical trial results, Vertex takes a step closer toward its long-stated goal of marketing new therapies capable of treating 90 percent of the genetic mutations that cause cystic fibrosis. https://buff.ly/2KCcYkC 

With new clinical trial results, Vertex takes a step closer toward its long-stated goal of marketing new therapies capable of treating 90 percent of the genetic mutations that cause cystic fibrosis. https://buff.ly/2KCcYkC 

Vertex cystic fibrosis drug combination shows strong results in pivotal clinical trials

With new clinical trial results, Vertex takes a step closer toward its long-stated goal of marketing new therapies capable of treating 90 percent of the genetic mutations that cause cystic…

Vertex: Two Phase 3 Studies Of VX-659 Triple Combination Met Primary Endpoint

Vertex Pharmaceuticals Inc. (VRTX) said Tuesday that two Phase 3 studies of the triple combination of the next-generation corrector VX-659, Tezacaftor and Ivacaftor met the primary endpoint of improvement in lung function in people with cystic fibrosis or CF.

Two Phase 3 Studies of the Triple Combination of VX-659, Tezacaftor and Ivacaftor Met Primary Endpoint of Improvement in Lung Function (ppFEV1) in People with Cystic Fibrosis

-Mean absolute improvement in ppFEV1 of 14.0 percentage points from baseline at week 4 in people with one F508del mutation and one minimal function mutation compared to placebo (p<0.0001)- -Mean absolute improvement in ppFEV1 of 10.0 percentage points from baseline at week 4 when VX-659 was added in people with two F508del mutations alre...

Vertex's Triple-Combo CF Drugs Dazzle in Preliminary Data from 2 Phase III Trials

Vertex Pharmaceuticals announced that two Phase III clinical trials of its triple combination of VX-659, tezacaftor and ivacaftor met their primary endpoint in cystic fibrosis (CF).

Histamine H4 Receptor AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi013 or SP9144 or GPCR105 or HRH4 Pipeline Review, H2 2018 [Report Updated: 18092018] Prices from USD $3500

Histamine H4 Receptor AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi013 or SP9144 or GPCR105 or HRH4 Pipeline Review, H2 2018SummaryHistamine H4 Receptor AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi013 or SP9144 or GPCR105 or HRH4 pipeline Target constitutes close to 6 molecules. The latest report Histamine H4 Receptor Pipeline Review, H2 2018, outlays comprehensive infor...

Forbius’ AVID200, a novel TGF-beta 1 & 3 Inhibitor, Cleared by the FDA to Commence Phase 1 Clinical Trial in Solid Tumors

AVID200 is a novel, rationally designed, highly potent TGF-beta 1 & 3 inhibitor Best-in-class efficacy and safety potential by selectively targeting principal oncogenic TGF-beta isoforms Reverses immunosuppression and renders tumors sensitive to checkpoint blockade in pre-clinical models ...

Vertex Pharmaceuticals Inc VRTX Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 09112018] Prices from USD $250

SummaryVertex Pharmaceuticals Inc Vertex is a biotechnology company that carries out the discovery, development and commercialization of transformative drugs for the treatment of serious and lifethreatening diseases. The company product portfolio includes Orkambi ivacaftor/lumacaftor and Kalydeco ivacaftor for the treatment of cystic fibrosis CF. Through its research and development RD efforts, th...

Human medicines European public assessment report (EPAR): Symkevi, tezacaftor / ivacaftor, Cystic Fibrosis, Date of authorisation: 31/10/2018, Status: Authorised

Human medicines European public assessment report (EPAR): Symkevi, tezacaftor / ivacaftor, Cystic Fibrosis, Date of authorisation: 31/10/2018, Status: Authorised

Advertisement
Quick Search
Advertisement
Advertisement

 

review and buy PulmoXen market research data and corporate reports here